• Meghan F Haas, Jessica Latchman, Ann M Guastella, David S Craig, and Young D Chang.
• Meghan F. Haas, DO, FACOI, Jessica Latchman, ARNP, Ann M. Guastella, ARNP, David S. Craig, PharmD, and Young D. Chang, MD, are with theDepartment of Supportive Care, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
• J Pain Palliat Care Pharmacother. 2022 Sep 1; 36 (3): 194-199.

AbstractHere, we describe a case of a patient with multiple myeloma who reported symptoms of lucid dreams. This patient was taking methadone for neoplasm related pain. The patient was also taking pregabalin which was initially started at dosing of 50 mg taken orally three times a day. Five days after initiation of pregabalin, the dosing was increased to 100 mg taken orally three times daily. The patient developed lucid dreams during a hospital stay and methadone was initially thought to be the cause of her lucid dreams. Methadone dosing was decreased with no success, and her lucid dreams persisted. On the patient's thirteenth day of hospital admission, the pregabalin dose was decreased from 100 mg three times a day to 75 mg twice daily. Five days later, the pregabalin was decreased from 75 mg twice daily to 50 mg twice daily. Pregabalin was continued for five more days and then discontinued. Resolution of the lucid dreams occurred following discontinuation of pregabalin. To our knowledge, this is the first reported case of an association between pregabalin and lucid dreams. Given that pregabalin is a widely used medication, we found this case to be relevant to describe this unique presentation.

8 keywords...

hide…